Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCorRx Inc. stock logo
BICX
BioCorRx
$0.34
+9.7%
$0.36
$0.20
$1.45
$5.78M0.1110,246 shs2,700 shs
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$4.85
+23.7%
$0.00
$0.91
$9.40
$89.51MN/A4.75 million shs18.35 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.24
$17.03M1.19166,266 shs4.12 million shs
Marpai, Inc. stock logo
MRAI
Marpai
$1.40
+0.4%
$1.10
$0.40
$1.68
$21.99M4.7420,439 shs103,573 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCorRx Inc. stock logo
BICX
BioCorRx
0.00%+13.33%+10.86%+10.75%-53.42%
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
+12.32%+186.13%-6.00%+391,999,900.00%+391,999,900.00%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-31.00%-72.69%
Marpai, Inc. stock logo
MRAI
Marpai
+5.98%+0.72%+33.33%+47.37%+118.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCorRx Inc. stock logo
BICX
BioCorRx
0.0488 of 5 stars
0.01.00.00.00.01.70.0
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCorRx Inc. stock logo
BICX
BioCorRx
0.00
N/AN/AN/A
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCorRx Inc. stock logo
BICX
BioCorRx
$90K64.25N/AN/A($1.14) per share-0.30
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$10.05M8.91N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Marpai, Inc. stock logo
MRAI
Marpai
$34.87M0.63N/AN/A($1.72) per share-0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCorRx Inc. stock logo
BICX
BioCorRx
-$3.77M-$0.41N/AN/A-11,600.00%N/A-1,074.47%8/11/2025 (Estimated)
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%6/12/2025 (Estimated)
Marpai, Inc. stock logo
MRAI
Marpai
-$28.75M-$1.82N/AN/A-85.70%N/A-100.23%8/5/2025 (Estimated)

Latest BICX, MRAI, BMGL, and ENZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
BioCorRx Inc. stock logo
BICX
BioCorRx
N/A-$0.06N/A-$0.06N/AN/A
3/31/2025Q4 2024
BioCorRx Inc. stock logo
BICX
BioCorRx
N/A-$0.08N/A-$0.08N/AN/A
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCorRx Inc. stock logo
BICX
BioCorRx
N/AN/AN/AN/AN/A
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCorRx Inc. stock logo
BICX
BioCorRx
N/A
0.04
0.04
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Marpai, Inc. stock logo
MRAI
Marpai
N/A
0.82
0.82

Institutional Ownership

CompanyInstitutional Ownership
BioCorRx Inc. stock logo
BICX
BioCorRx
N/A
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Marpai, Inc. stock logo
MRAI
Marpai
49.75%

Insider Ownership

CompanyInsider Ownership
BioCorRx Inc. stock logo
BICX
BioCorRx
21.40%
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Marpai, Inc. stock logo
MRAI
Marpai
61.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCorRx Inc. stock logo
BICX
BioCorRx
317.01 million11.92 millionNot Optionable
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
3618.46 millionN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Marpai, Inc. stock logo
MRAI
Marpai
15015.71 million5.61 millionNo Data

Recent News About These Companies

Marpai (NASDAQ:MRAI) Trading Up 0.7% - Here's Why
Marpai appoints new COO to accelerate growth
Market Access RICI Agriculture UCITS (MRAI)
Marpai, Inc. (MRAI) Q4 2024 Earnings Call Transcript
MARPAI ANNOUNCES GENERAL UPDATES FOR Q4

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCorRx stock logo

BioCorRx OTCMKTS:BICX

$0.34 +0.03 (+9.68%)
As of 05/30/2025 03:48 PM Eastern

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Basel Medical Group stock logo

Basel Medical Group NASDAQ:BMGL

$4.85 +0.93 (+23.72%)
As of 12:40 PM Eastern

OUR MISSION Basel Medical transcends the role of a conventional healthcare provider. We strive for excellence in medical services and aim to serve as a beacon of hope for patients across Singapore and Southeast Asia. Our mission encompasses the four following commitments: Patient–Centered Care. We prioritize our patient’s wellbeing above all else. Innovation. We strive for excellence through innovation and expertise. Global Accessibility. We believe that quality healthcare should be universally available. Continuous Improvement. We constantly improve our services to meet evolving patient needs. With over 20 years of medical services experience, Basel Medical’s journey began with a simple commitment – to restore healthy and active lifestyles, one at a time. Today, that commitment has transformed into a vision for innovation, growth and far-reaching impact. We rely on an experienced group of medical practitioners to provide a wide spectrum of general and subspecialized orthopedic, trauma, sports medicine and neurosurgical services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, minimally invasive orthopedic procedures and other complex neurosurgical procedures. We operate our two clinics at Gleneagles Medical Centre in Singapore and currently have five medical practitioners practicing with Basel Medical (together with its subsidiaries, the “Group”), comprising four orthopedic specialists and one neurosurgery specialist. The services provided by our clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine and neurological conditions and our clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services, while more complex surgical procedures are performed at operating theaters of other hospitals with such facilities. Our Group has a patient-oriented philosophy of providing personalized, quality and integrated medical care. We aim to be a one-stop integrated healthcare provider for all musculoskeletal-related medical care, including post-surgery rehabilitation services such as physiotherapy as well as other ancillary services such as pain management. Within the next 12 to 18 months, we intend to actively seek acquisition and collaboration partners in Singapore and Malaysia. Our acquisition and collaboration targets include general practitioner (GP) clinics and specialist clinics that complement our orthopedic services, particularly those focused on the musculoskeletal system, aging treatments, physiotherapy and occupational therapists. Our goal is to become an internationally known medical services provider in the Southeast Asian market, with a presence in at least four Southeast Asia countries (potentially covering Singapore, Malaysia, Indonesia and Thailand) within the next three years. As of the date of this prospectus, we have not identified such targets. Basel Medical was incorporated in the BVI on August 10, 2023 with registered number 2129740 as a BVI business company with liability limited by shares. Our BVI registered office is located at Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands VG1110. Our principal executive offices are located in Singapore at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore. Our agent for service of process in the United States is Puglisi & Associates at 850 Library Avenue, Suite 204, Newark, Delaware.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Marpai stock logo

Marpai NASDAQ:MRAI

$1.40 +0.01 (+0.36%)
As of 06/2/2025 03:38 PM Eastern

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.